ID APC11_HUMAN Reviewed; 84 AA. AC Q9NYG5; A8MTT2; B7ZW64; Q502X9; Q9BW64; Q9P0R2; DT 29-AUG-2001, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 27-MAR-2024, entry version 203. DE RecName: Full=Anaphase-promoting complex subunit 11; DE Short=APC11; DE AltName: Full=Cyclosome subunit 11; DE AltName: Full=Hepatocellular carcinoma-associated RING finger protein; GN Name=ANAPC11; ORFNames=HSPC214; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND SUBCELLULAR RP LOCATION. RX PubMed=11573242; DOI=10.1002/jcb.1217; RA Chan A.H., Lee S.M.Y., Chim S.S., Kok L.D., Waye M.M.Y., Lee C.Y., RA Fung K.P., Tsui S.K.W.; RT "Molecular cloning and characterization of a RING-H2 finger protein, RT ANAPC11, the human homolog of yeast Apc11p."; RL J. Cell. Biochem. 83:249-258(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Li N., Wan T., Zhang W., Cao X.; RT "Novel human APC11 anaphase-promoting complex subunit."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Umbilical cord blood; RX PubMed=11042152; DOI=10.1101/gr.140200; RA Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G., RA Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W., RA Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.; RT "Cloning and functional analysis of cDNAs with open reading frames for 300 RT previously undefined genes expressed in CD34+ hematopoietic stem/progenitor RT cells."; RL Genome Res. 10:1546-1560(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, Skin, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP IDENTIFICATION IN APC/C COMPLEX. RX PubMed=10922056; DOI=10.1073/pnas.97.16.8973; RA Gmachl M., Gieffers C., Podtelejnikov A.V., Mann M., Peters J.-M.; RT "The RING-H2 finger protein APC11 and the E2 enzyme UBC4 are sufficient to RT ubiquitinate substrates of the anaphase-promoting complex."; RL Proc. Natl. Acad. Sci. U.S.A. 97:8973-8978(2000). RN [7] RP FUNCTION, MUTAGENESIS, AND INTERACTION WITH ANAPC2 AND UBE2D2. RX PubMed=11739784; DOI=10.1091/mbc.12.12.3839; RA Tang Z., Li B., Bharadwaj R., Zhu H., Oezkan E., Hakala K., Deisenhofer J., RA Yu H.; RT "APC2 cullin protein and APC11 RING protein comprise the minimal ubiquitin RT ligase module of the anaphase-promoting complex."; RL Mol. Biol. Cell 12:3839-3851(2001). RN [8] RP FUNCTION OF THE APC/C. RX PubMed=18485873; DOI=10.1016/j.cell.2008.04.012; RA Jin L., Williamson A., Banerjee S., Philipp I., Rape M.; RT "Mechanism of ubiquitin-chain formation by the human anaphase-promoting RT complex."; RL Cell 133:653-665(2008). RN [9] RP ELECTRON MICROSCOPY OF THE APC/C. RX PubMed=16364912; DOI=10.1016/j.molcel.2005.11.008; RA Dube P., Herzog F., Gieffers C., Sander B., Riedel D., Mueller S.A., RA Engel A., Peters J.-M., Stark H.; RT "Localization of the coactivator Cdh1 and the cullin subunit Apc2 in a RT cryo-electron microscopy model of vertebrate APC/C."; RL Mol. Cell 20:867-879(2005). RN [10] RP STRUCTURE BY ELECTRON MICROSCOPY (7.4 ANGSTROMS) OF THE APC/C, AND SUBUNIT. RX PubMed=25043029; DOI=10.1038/nature13543; RA Chang L., Zhang Z., Yang J., McLaughlin S.H., Barford D.; RT "Molecular architecture and mechanism of the anaphase-promoting complex."; RL Nature 513:388-393(2014). RN [11] {ECO:0007744|PDB:4UI9, ECO:0007744|PDB:5A31} RP STRUCTURE BY ELECTRON MICROSCOPY (3.60 ANGSTROMS) OF APC/C, AND SUBUNIT. RX PubMed=26083744; DOI=10.1038/nature14471; RA Chang L., Zhang Z., Yang J., McLaughlin S.H., Barford D.; RT "Atomic structure of the APC/C and its mechanism of protein RT ubiquitination."; RL Nature 522:450-454(2015). CC -!- FUNCTION: Together with the cullin protein ANAPC2, constitutes the CC catalytic component of the anaphase promoting complex/cyclosome CC (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls CC progression through mitosis and the G1 phase of the cell cycle. The CC APC/C complex acts by mediating ubiquitination and subsequent CC degradation of target proteins: it mainly mediates the formation of CC 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the CC formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. May CC recruit the E2 ubiquitin-conjugating enzymes to the complex. CC {ECO:0000269|PubMed:11739784, ECO:0000269|PubMed:18485873}. CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: The mammalian APC/C is composed at least of 14 distinct CC subunits ANAPC1, ANAPC2, CDC27/APC3, ANAPC4, ANAPC5, CDC16/APC6, CC ANAPC7, CDC23/APC8, ANAPC10, ANAPC11, CDC26/APC12, ANAPC13, ANAPC15 and CC ANAPC16 that assemble into a complex of at least 19 chains with a CC combined molecular mass of around 1.2 MDa; APC/C interacts with FZR1 CC and FBXO5 (PubMed:26083744, PubMed:10922056, PubMed:25043029). CC Interacts with the cullin domain of ANAPC2 (PubMed:11739784). Interacts CC with UBE2D2 (PubMed:11739784). {ECO:0000269|PubMed:10922056, CC ECO:0000269|PubMed:11739784, ECO:0000269|PubMed:25043029, CC ECO:0000269|PubMed:26083744}. CC -!- INTERACTION: CC Q9NYG5; P28799: GRN; NbExp=3; IntAct=EBI-2130187, EBI-747754; CC Q9NYG5; O43933: PEX1; NbExp=3; IntAct=EBI-2130187, EBI-988601; CC Q9NYG5-2; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-12224467, EBI-11524452; CC Q9NYG5-2; Q8NDZ0: BEND2; NbExp=3; IntAct=EBI-12224467, EBI-954079; CC Q9NYG5-2; Q02930-3: CREB5; NbExp=3; IntAct=EBI-12224467, EBI-10192698; CC Q9NYG5-2; P53672: CRYBA2; NbExp=3; IntAct=EBI-12224467, EBI-750444; CC Q9NYG5-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-12224467, EBI-3867333; CC Q9NYG5-2; Q86UW9: DTX2; NbExp=3; IntAct=EBI-12224467, EBI-740376; CC Q9NYG5-2; Q12805: EFEMP1; NbExp=3; IntAct=EBI-12224467, EBI-536772; CC Q9NYG5-2; O95967: EFEMP2; NbExp=3; IntAct=EBI-12224467, EBI-743414; CC Q9NYG5-2; O43559: FRS3; NbExp=3; IntAct=EBI-12224467, EBI-725515; CC Q9NYG5-2; O95872: GPANK1; NbExp=3; IntAct=EBI-12224467, EBI-751540; CC Q9NYG5-2; Q9H2F3: HSD3B7; NbExp=3; IntAct=EBI-12224467, EBI-3918847; CC Q9NYG5-2; Q8NA54: IQUB; NbExp=3; IntAct=EBI-12224467, EBI-10220600; CC Q9NYG5-2; Q8IUC1: KRTAP11-1; NbExp=3; IntAct=EBI-12224467, EBI-1052037; CC Q9NYG5-2; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-12224467, EBI-11953846; CC Q9NYG5-2; Q3LHN2: KRTAP19-2; NbExp=3; IntAct=EBI-12224467, EBI-12196745; CC Q9NYG5-2; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-12224467, EBI-9996449; CC Q9NYG5-2; Q9BYR6: KRTAP3-3; NbExp=3; IntAct=EBI-12224467, EBI-3957694; CC Q9NYG5-2; Q3LI64: KRTAP6-1; NbExp=3; IntAct=EBI-12224467, EBI-12111050; CC Q9NYG5-2; Q3LI66: KRTAP6-2; NbExp=3; IntAct=EBI-12224467, EBI-11962084; CC Q9NYG5-2; Q8TDS5: OXER1; NbExp=3; IntAct=EBI-12224467, EBI-12813389; CC Q9NYG5-2; Q7Z4N8: P4HA3; NbExp=3; IntAct=EBI-12224467, EBI-10181968; CC Q9NYG5-2; P54646: PRKAA2; NbExp=3; IntAct=EBI-12224467, EBI-1383852; CC Q9NYG5-2; O43741: PRKAB2; NbExp=3; IntAct=EBI-12224467, EBI-1053424; CC Q9NYG5-2; Q93062-3: RBPMS; NbExp=3; IntAct=EBI-12224467, EBI-740343; CC Q9NYG5-2; Q96LM6: SPMIP9; NbExp=3; IntAct=EBI-12224467, EBI-743976; CC Q9NYG5-2; Q8N8B7-2: TCEANC; NbExp=3; IntAct=EBI-12224467, EBI-11955057; CC Q9NYG5-2; Q08117-2: TLE5; NbExp=3; IntAct=EBI-12224467, EBI-11741437; CC Q9NYG5-2; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-12224467, EBI-12040603; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11573242}. Nucleus CC {ECO:0000269|PubMed:11573242}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9NYG5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9NYG5-2; Sequence=VSP_012347; CC -!- TISSUE SPECIFICITY: Expressed at high levels in skeletal muscle and CC heart; in moderate levels in brain, kidney, and liver; and at low CC levels in colon, thymus, spleen, small intestine, placenta, lung and CC peripheral blood leukocyte. {ECO:0000269|PubMed:11573242}. CC -!- DOMAIN: The RING-type zinc finger domain coordinates an additional CC third zinc ion. CC -!- PTM: Auto-ubiquitinated. CC -!- SIMILARITY: Belongs to the RING-box family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF36134.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF247565; AAF65816.1; -; mRNA. DR EMBL; AF247789; AAL95694.1; -; mRNA. DR EMBL; AF151048; AAF36134.1; ALT_FRAME; mRNA. DR EMBL; AC145207; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000607; AAH00607.2; -; mRNA. DR EMBL; BC066308; AAH66308.1; -; mRNA. DR EMBL; BC095454; AAH95454.1; -; mRNA. DR EMBL; BC104641; AAI04642.1; -; mRNA. DR EMBL; BC171892; AAI71892.1; -; mRNA. DR EMBL; BC171898; AAI71898.1; -; mRNA. DR EMBL; BC171899; AAI71899.1; -; mRNA. DR EMBL; BC171900; AAI71900.1; -; mRNA. DR CCDS; CCDS11789.1; -. [Q9NYG5-1] DR CCDS; CCDS32769.1; -. [Q9NYG5-2] DR RefSeq; NP_001002244.1; NM_001002244.2. [Q9NYG5-2] DR RefSeq; NP_001002245.1; NM_001002245.2. [Q9NYG5-1] DR RefSeq; NP_001002246.1; NM_001002246.2. [Q9NYG5-1] DR RefSeq; NP_001002247.1; NM_001002247.2. [Q9NYG5-1] DR RefSeq; NP_001002248.1; NM_001002248.2. [Q9NYG5-1] DR RefSeq; NP_001002249.1; NM_001002249.2. [Q9NYG5-1] DR RefSeq; NP_001276343.1; NM_001289414.1. [Q9NYG5-1] DR RefSeq; NP_001276344.1; NM_001289415.1. [Q9NYG5-1] DR RefSeq; NP_001276345.1; NM_001289416.1. [Q9NYG5-1] DR RefSeq; NP_001276346.1; NM_001289417.1. [Q9NYG5-1] DR RefSeq; NP_001276349.1; NM_001289420.1. DR RefSeq; NP_057560.8; NM_016476.11. [Q9NYG5-1] DR PDB; 2MT5; NMR; -; A=17-84. DR PDB; 4R2Y; X-ray; 1.76 A; A/B/C/D=17-84. DR PDB; 4UI9; EM; 3.60 A; B=1-84. DR PDB; 5A31; EM; 4.30 A; B=1-84. DR PDB; 5G04; EM; 4.00 A; B=1-84. DR PDB; 5G05; EM; 3.40 A; B=1-84. DR PDB; 5JG6; X-ray; 2.00 A; A/D=17-84. DR PDB; 5KHR; EM; 6.10 A; B=1-84. DR PDB; 5KHU; EM; 4.80 A; B=1-84. DR PDB; 5L9T; EM; 6.40 A; B=1-84. DR PDB; 5L9U; EM; 6.40 A; B=1-84. DR PDB; 5LCW; EM; 4.00 A; B=1-84. DR PDB; 6Q6G; EM; 3.20 A; C=1-84. DR PDB; 6Q6H; EM; 3.20 A; C=1-84. DR PDB; 6TLJ; EM; 3.80 A; B=1-84. DR PDB; 6TM5; EM; 3.90 A; B=1-84. DR PDB; 6TNT; EM; 3.78 A; B=1-84. DR PDB; 7QE7; EM; 2.90 A; C=1-84. DR PDB; 8PKP; EM; 3.20 A; C=1-84. DR PDB; 8TAR; EM; 4.00 A; C=1-84. DR PDB; 8TAU; EM; 3.50 A; C=1-84. DR PDBsum; 2MT5; -. DR PDBsum; 4R2Y; -. DR PDBsum; 4UI9; -. DR PDBsum; 5A31; -. DR PDBsum; 5G04; -. DR PDBsum; 5G05; -. DR PDBsum; 5JG6; -. DR PDBsum; 5KHR; -. DR PDBsum; 5KHU; -. DR PDBsum; 5L9T; -. DR PDBsum; 5L9U; -. DR PDBsum; 5LCW; -. DR PDBsum; 6Q6G; -. DR PDBsum; 6Q6H; -. DR PDBsum; 6TLJ; -. DR PDBsum; 6TM5; -. DR PDBsum; 6TNT; -. DR PDBsum; 7QE7; -. DR PDBsum; 8PKP; -. DR PDBsum; 8TAR; -. DR PDBsum; 8TAU; -. DR AlphaFoldDB; Q9NYG5; -. DR BMRB; Q9NYG5; -. DR EMDB; EMD-10516; -. DR EMDB; EMD-10518; -. DR EMDB; EMD-10536; -. DR EMDB; EMD-13931; -. DR EMDB; EMD-17751; -. DR EMDB; EMD-2924; -. DR EMDB; EMD-2925; -. DR EMDB; EMD-3385; -. DR EMDB; EMD-3386; -. DR EMDB; EMD-3387; -. DR EMDB; EMD-3388; -. DR EMDB; EMD-3389; -. DR EMDB; EMD-3390; -. DR EMDB; EMD-4037; -. DR EMDB; EMD-41140; -. DR EMDB; EMD-41142; -. DR EMDB; EMD-4465; -. DR EMDB; EMD-4466; -. DR EMDB; EMD-4467; -. DR SMR; Q9NYG5; -. DR BioGRID; 119591; 81. DR ComplexPortal; CPX-1860; Anaphase-promoting core complex. DR DIP; DIP-52741N; -. DR IntAct; Q9NYG5; 45. DR STRING; 9606.ENSP00000349957; -. DR iPTMnet; Q9NYG5; -. DR PhosphoSitePlus; Q9NYG5; -. DR BioMuta; ANAPC11; -. DR DMDM; 19924286; -. DR EPD; Q9NYG5; -. DR jPOST; Q9NYG5; -. DR MassIVE; Q9NYG5; -. DR MaxQB; Q9NYG5; -. DR PeptideAtlas; Q9NYG5; -. DR ProteomicsDB; 83227; -. [Q9NYG5-1] DR ProteomicsDB; 83228; -. [Q9NYG5-2] DR Pumba; Q9NYG5; -. DR Antibodypedia; 19841; 419 antibodies from 37 providers. DR DNASU; 51529; -. DR Ensembl; ENST00000344877.10; ENSP00000339695.5; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000357385.7; ENSP00000349957.3; ENSG00000141552.18. [Q9NYG5-2] DR Ensembl; ENST00000392376.7; ENSP00000376181.3; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000571024.6; ENSP00000461648.2; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000571570.5; ENSP00000458143.1; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000571874.6; ENSP00000459200.2; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000572639.5; ENSP00000460678.1; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000572851.6; ENSP00000458265.2; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000574924.6; ENSP00000460064.2; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000575195.2; ENSP00000458515.2; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000577747.5; ENSP00000463567.1; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000578550.5; ENSP00000464615.1; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000579978.5; ENSP00000463640.1; ENSG00000141552.18. [Q9NYG5-1] DR Ensembl; ENST00000583839.1; ENSP00000463598.1; ENSG00000141552.18. [Q9NYG5-1] DR GeneID; 51529; -. DR KEGG; hsa:51529; -. DR MANE-Select; ENST00000344877.10; ENSP00000339695.5; NM_001002248.3; NP_001002248.1. DR UCSC; uc002kbv.3; human. [Q9NYG5-1] DR AGR; HGNC:14452; -. DR CTD; 51529; -. DR DisGeNET; 51529; -. DR GeneCards; ANAPC11; -. DR HGNC; HGNC:14452; ANAPC11. DR HPA; ENSG00000141552; Low tissue specificity. DR MIM; 614534; gene. DR neXtProt; NX_Q9NYG5; -. DR OpenTargets; ENSG00000141552; -. DR PharmGKB; PA24787; -. DR VEuPathDB; HostDB:ENSG00000141552; -. DR GeneTree; ENSGT00550000075186; -. DR HOGENOM; CLU_115512_0_2_1; -. DR InParanoid; Q9NYG5; -. DR OMA; QWRWDTG; -. DR OrthoDB; 4663070at2759; -. DR PhylomeDB; Q9NYG5; -. DR TreeFam; TF354219; -. DR PathwayCommons; Q9NYG5; -. DR Reactome; R-HSA-141430; Inactivation of APC/C via direct inhibition of the APC/C complex. DR Reactome; R-HSA-174048; APC/C:Cdc20 mediated degradation of Cyclin B. DR Reactome; R-HSA-174084; Autodegradation of Cdh1 by Cdh1:APC/C. DR Reactome; R-HSA-174154; APC/C:Cdc20 mediated degradation of Securin. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-174184; Cdc20:Phospho-APC/C mediated degradation of Cyclin A. DR Reactome; R-HSA-176407; Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase. DR Reactome; R-HSA-176408; Regulation of APC/C activators between G1/S and early anaphase. DR Reactome; R-HSA-176409; APC/C:Cdc20 mediated degradation of mitotic proteins. DR Reactome; R-HSA-176412; Phosphorylation of the APC/C. DR Reactome; R-HSA-179409; APC-Cdc20 mediated degradation of Nek2A. DR Reactome; R-HSA-2467813; Separation of Sister Chromatids. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-68867; Assembly of the pre-replicative complex. DR Reactome; R-HSA-69017; CDK-mediated phosphorylation and removal of Cdc6. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-9687136; Aberrant regulation of mitotic exit in cancer due to RB1 defects. DR Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation. DR SignaLink; Q9NYG5; -. DR SIGNOR; Q9NYG5; -. DR UniPathway; UPA00143; -. DR BioGRID-ORCS; 51529; 746 hits in 1212 CRISPR screens. DR ChiTaRS; ANAPC11; human. DR GeneWiki; ANAPC11; -. DR GenomeRNAi; 51529; -. DR Pharos; Q9NYG5; Tbio. DR PRO; PR:Q9NYG5; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9NYG5; Protein. DR Bgee; ENSG00000141552; Expressed in right testis and 101 other cell types or tissues. DR ExpressionAtlas; Q9NYG5; baseline and differential. DR GO; GO:0005680; C:anaphase-promoting complex; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0097602; F:cullin family protein binding; IDA:MGI. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI. DR GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; IDA:MGI. DR GO; GO:0008270; F:zinc ion binding; IEA:InterPro. DR GO; GO:0031145; P:anaphase-promoting complex-dependent catabolic process; NAS:ComplexPortal. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0000278; P:mitotic cell cycle; TAS:UniProtKB. DR GO; GO:0045842; P:positive regulation of mitotic metaphase/anaphase transition; IDA:UniProt. DR GO; GO:0070979; P:protein K11-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB. DR GO; GO:0051445; P:regulation of meiotic cell cycle; NAS:ComplexPortal. DR GO; GO:0007346; P:regulation of mitotic cell cycle; NAS:ComplexPortal. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IBA:GO_Central. DR CDD; cd16456; RING-H2_APC11; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR024991; RING-H2_APC11. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR PANTHER; PTHR11210:SF1; ANAPHASE-PROMOTING COMPLEX SUBUNIT 11; 1. DR PANTHER; PTHR11210; RING BOX; 1. DR Pfam; PF12861; zf-ANAPC11; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50089; ZF_RING_2; 1. DR Genevisible; Q9NYG5; HS. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell cycle; Cell division; Cytoplasm; KW Metal-binding; Mitosis; Nucleus; Reference proteome; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..84 FT /note="Anaphase-promoting complex subunit 11" FT /id="PRO_0000055747" FT ZN_FING 34..77 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT BINDING 23 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 26 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 34 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000250" FT BINDING 37 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000250" FT BINDING 44 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000250" FT BINDING 51 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 53 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 56 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 58 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000250" FT BINDING 59 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 73 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 76 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT VAR_SEQ 38..84 FT /note="KVPGDDCPLVWGQCSHCFHMHCILKWLHAQQVQQHCPMCRQEWKFKE -> P FT LHGESISRCLGWCPQPVPVLGGRAHPQVPINTASPTPGQHTGSLMSREESSRSPDPTPP FT ALDQETSSLLRCTSPWCLDHSCDLFGITDQVSADGPRACRQGARRRLPAGVGPVLPLLP FT HALHPQVAARTAGAAALPHVPPGMEVQGVRPDLALAGGAS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_012347" FT MUTAGEN 23 FT /note="C->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 26 FT /note="C->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 34 FT /note="C->S: Slightly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 37 FT /note="C->S: Slightly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 44 FT /note="C->S: Slightly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 51 FT /note="C->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 53 FT /note="H->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 56 FT /note="H->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 58 FT /note="H->S: Slightly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 59 FT /note="C->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 73 FT /note="C->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT MUTAGEN 76 FT /note="C->S: Greatly reduces autoubiquitination activity; FT in isoform 1." FT /evidence="ECO:0000269|PubMed:11739784" FT STRAND 2..16 FT /evidence="ECO:0007829|PDB:7QE7" FT STRAND 19..22 FT /evidence="ECO:0007829|PDB:6Q6G" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:4R2Y" FT STRAND 29..32 FT /evidence="ECO:0007829|PDB:6Q6G" FT HELIX 35..37 FT /evidence="ECO:0007829|PDB:4R2Y" FT TURN 38..41 FT /evidence="ECO:0007829|PDB:4R2Y" FT STRAND 46..49 FT /evidence="ECO:0007829|PDB:4R2Y" FT STRAND 50..52 FT /evidence="ECO:0007829|PDB:2MT5" FT STRAND 54..56 FT /evidence="ECO:0007829|PDB:4R2Y" FT HELIX 57..67 FT /evidence="ECO:0007829|PDB:4R2Y" FT STRAND 68..70 FT /evidence="ECO:0007829|PDB:5JG6" FT STRAND 76..79 FT /evidence="ECO:0007829|PDB:4R2Y" SQ SEQUENCE 84 AA; 9841 MW; EACBD5A54FDC11AE CRC64; MKVKIKCWNG VATWLWVAND ENCGICRMAF NGCCPDCKVP GDDCPLVWGQ CSHCFHMHCI LKWLHAQQVQ QHCPMCRQEW KFKE //